TP53 and colorectal carcinoma: In the CRC versus NAT comparison, 26.9% of TP53 pathway genes (18 from 67 genes) showed significant DNA methylation alterations in their promoter regions with at least a 10% methylation difference (p < 0.05, Δβ ≥ 0.1) (Table 1).